Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab plus ipilimumab or chemotherapy versus chemotherapy in previously untreated unresectable or metastatic urothelial carcinoma
CTR20180252Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, ipilimumab, gemcitabine, cisplatin, carboplatin in transitional cell carcinoma (TCC), sponsored by Bristol Myers Squibb. Started Jul 2018; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20180252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180252.